UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2026

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

175 Derby St., Bld. 27
Hingham, MA 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On March 17, 2026, Microbot Medical Inc. (the "Company") issued a press release announcing that it will be participating in the Roth Annual Growth Conference, being held March 22-24, 2026, in Laguna Niguel, CA. Harel Gadot, CEO, President & Chairman of the Company, will present live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23, 2026, and a live webcast may be accessed via the 'Events' section of the Company's website at www.microbotmedical.com. The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference.

In addition, the Company released updated presentation materials. The presentation materials may be accessed via the 'Investors' section, under 'IR Resources' and then 'Additional Resources,' of the Company's website at www.microbotmedical.com. The Company is not undertaking to update these presentation materials. The presentation materials are also furnished as Exhibit 99.2 to this Current Report on Form 8-K, and are incorporated herein by reference.

The information in this Item 7.01, and Exhibits 99.1 and 99.2, are being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibits 99.1 or 99.2.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release
99.2	Presentation Materials
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: March 17, 2026

Exhibit 99.1

Microbot Medical® to Participate at the 38th Annual Roth Conference

Live Webcast of Fireside Q&A Discussion on Monday, March 23, 2026 at 4:00 pm PT as it Nears its Full Market Release of the LIBERTY® in April

HINGHAM, Mass., March 17, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that it will participate in the Roth Annual Growth Conference, being held March 22-24 in Laguna Niguel, CA. The conference is a premier event that brings together growth companies, institutional investors, and industry leaders for presentations, panel discussions, and one-on-one meetings. Harel Gadot, CEO, President & Chairman of Microbot Medical will be presenting live via a fireside Q&A discussion at 4:00 pm PT on Monday, March 23rd. Mr. Gadot will highlight the Company's recent achievements, and how LIBERTY is a unique and differentiated solution, addressing critical unmet healthcare needs, including physician safety and staffing issues.

The presentation will be a live webcast and may be accessed via the 'Investors' section on Microbot Medical's website at https://ir.microbotmedical.com/. Additionally, Mr. Gadot will be meeting growth-oriented institutional investors and other interested parties on Monday, March 23rd, through a series of pre-scheduled one-on-one meetings. Investors should reach out to their Roth sales representatives or contact mpolyviou@evcgroup.com to schedule a one-on-one meeting.

"We believe the ongoing progress and success of our limited market release, driven by multi-site customer traction and procedural diversity, has validated our strategy to support the full market release, which is on target for next month," commented Mr. Gadot. "We believe the Roth conference is an ideal stage to showcase this commercial momentum and introduce our differentiated growth story to a diverse audience, to support our current position and future growth."

LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain. The Company commenced the limited market release of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, allowing the Company to showcase LIBERTY with the goal to deepen market adoption.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY® Endovascular Robotic System is the world's first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.

Learn more at www.microbotmedical.com and connect on LinkedIn and X.

Safe Harbor

Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "contemplates," "continues," "could," "forecasts," "intends," "may," "might," "possible," "potential," "predicts," "projects," "should," "would," "will," "believes," "plans," "anticipates," "expects," "estimates" and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contacts:

IR@microbotmedical.com
Media@microbotmedical.com


Driving the Future of Intervention™
liberty
liberty
microbot
medical

Safe Harbor Statement

This document (together with any oral statements made in connection with this document) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, Inc. and its subsidiaries. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: market conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system; uncertainty in the results of regulatory pathways and regulatory approvals and the development of future versions or applications for the system; uncertainty resulting from political, social and geopolitical conditions; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; maintenance of intellectual property rights; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Pivotal Company Development

September 2025

November 2025

Microbot Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.

Company Completes the Required Infrastructure to Support the Introduction of LIBERTY® to the U.S. Market with the Hiring of the Core Commercial Team and Establishing Logistic Partnership

Interest and Overwhelmingly Positive Feedback from Physicians and Hospital Administrators at Recent Meetings Validates Limited Market Release of LIBERTY®

HINGHAM, Mass., November 5, 2025 – Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced that its LIBERTY® System, the first FDA cleared single-use, remotely operated robotic system for peripheral endovascular procedures, is now commercially available in the U.S. The Limited Market Release (LMR) will introduce LIBERTY® to selected high procedure volume regions where the Company already experienced preliminary demand for LIBERTY®. The LMR will focus on collecting real-world insights from potential high-volume users to guide responsible growth and ensure consistent quality and performance, leading to the expected Full Market Release (FMR) during the Society of Interventional Radiology (SIR), the largest U.S. medical conference for Interventional Radiology, in April 2026.

"We are excited to enter the commercialization phase of LIBERTY®. We are building a new robotic category with the introduction of LIBERTY®, the world's first single-use robotic

Pivotal Company Development

Microbot Medical® Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY® Endovascular Robotic System

Microbot Medical Inc.
November 26, 2025 • 4 min read

1

Tampa General Hospital is the First Health System in Florida to Adopt the LIBERTY® Endovascular Robotic System

Microbot Medical Inc.
Tue, February 24, 2026 at 8:30 AM EST • 5 min read

The Market

Robotic Assisted Surgery Market is Big and Growing…

Robotic Assisted Surgery Market Size, Global
2019-2030



Source: GlobalData; Note: Includes Robotic Surgical Systems and Accessories

…So No Wonder Everyone Wants to Play in it…

Is There a Blue Ocean?

Endovascular Is a Clear Blue Ocean

	Laproscopy	Endoluminal	Microsurgery
FDA Clearance/ Approval	INTUITIVE, ASENSUS SURGICAL, MOON SURGICAL, Dex Surgical, MOMENTIS SURGICAL, VIRTUALINCISION, freehand, Levita MAGNETICS, AKTORmed ROBOTIC SURGERY, HUMAN XTENSIONS	INTUITIVE, Johnson&Johnson, Noah Medical	VENUSCONCEPT, Leica MICROSYSTEMS, GALEN ROBOTICS, OLYMPUS, AESCULAP B BRAUN SHARING EXPERTISE, MMI, synaptive, iotamotion Hearing, advanced.

	Hard Tissue	Soft Tissue	Vascular Navigation
FDA Clearance/ Approval	Medtronic, THINK SURGICAL, POINT, GLOBUS MEDICAL, Johnson&Johnson, atec, neocis, ZIMMER BIOMET, ecential robotics, stryker, Corin, CUREXO, smith&nephew	edap tms, MONTERIS, QUANTUM surgical, BRAINLAB, ACCURAY, ZAP, PROCEPT BioRobotics, CASCINATION, insight medbotics, ACOUSTIC MEDISYSTEMS, NDR Medical Technology, INTERVENTIONAL SYSTEMS, Perfint, Dominion Aesthetic Technologies, Inc., HISTOSONICS, biobot, ZIMMER BIOMET, INSIGHTEC, RENISHAW	STEREOTAXIS

USA Endovascular Market





Large and Emergent Market

- **>6 million annual endovascular procedures performed in the US (15 million worldwide)**
- **>$40B spent annually** in the US
- Performed by **15,000 physicians**
  - 9,000 interventional cardiologists
  - 3,000 interventional radiologists[1]
  - 3,000 vascular surgeons
- Performed at **8,000 facilities**
  - 3,500 hospitals
  - 4,500 ambulatory centers (ASCs/OBLs)
- Many **endovascular procedures are emergent**, life and limb saving interventions



Source: AcuityMD procedure and physician database
1. Includes interventional neuroradiologists which is a sub-specialty of IR

Supported by Interventionalists

Do you anticipate that you will begin using a robotic-assisted vascular intervention system in the future?



N=200 interventionalists, data on file

Growing Unmet Needs

microbot medical

AMA's 2026 public health initiative calls for expanded **radiation safety protections** and **ergonomic workplace design** to reduce clinician injury and improve long-term workforce health.[1]

Radiation & Ergonomic Risks[2]

Interventionalists have:

- 6× higher risk of cataracts
- 3× higher risk of malignancy

Ergonomic / Musculoskeletal Risks:

- 66% reported musculoskeletal pain related to wearing lead protective equipment
- 60% reported at least one orthopedic injury

Staff Shortage

- IR is ranked 2nd in specialties facing the greatest physician shortages[3]
- Healthcare faces staff shortages of 85K+ by 2036[4]
- Nearly 50% of physicians report burnout[4]
- 1 in 5 physicians report experiencing depression, exacerbating workforce gaps[4]

Access to Quality Care[5]

- 20% of Americans live in rural areas where only 10% of doctors practice
- 80% of rural Americans are medically underserved
- ~200 rural hospitals have closed since 2005

1. AMA adopts new public health policies to improve health of nation | American Medical Association
2. https://evtoday.com/articles/2025-early-career-insights-2/radiation-safety-dont-wait-until-its-too-late?utm_source=linkedin&utm_medium=newsletter&utm_campaign=etDE1125 Gore
3. https://axuall.com/wp-content/uploads/2025/06/Axuall- -2025-Clinician-Workforce-Insights-Report-final.pdf
4. https://nihcm.org/newsletter/rising-healthcare-workforce-shortage
5. https://nihcm.org/publications/rural-health-needs-in-america-challenges-and-solutions
6. https://www.cvirconline.org/

Endovascular Robotics: Limited Adoption



The Barriers

Multiple Barriers Leading to Low Penetration

Extended set-up time

Special training, long learning curve

Large footprint

Capital expense

Cumbersome and expensive disposables

Dedicated infrastructure

Change the Conversation

The Solution

A New Robotics Category

Fully Disposable & Single-use Robotic System is Designed for Access and Adoption

External Benefits

- Single-use, disposable system eliminates capital and infrastructure costs
- Sterile, ready-to-use design enables rapid setup
- No capital investment removes upfront costs and long-term risks
- No service contracts or annual service agreements required

Internal Benefits

- First mover advantage
- Predictable recurring revenue from hospital utilization
- Faster sales cycle for quicker acquisition
- Disposable components only reduce operational expenses
- No field service needed, further reducing operational expenses

Differentiated Robotic Solution

The LIBERTY® Endovascular Robotic System is disruptive technology designed to change the standard of care for endovascular procedures

- Single-use, fully-disposable without need for capital investment
- Empowers physicians to precisely steer guidewires and catheters using a handheld remote control away from the radiation source
- Small footprint that integrates into current procedure workflow
- No additional infrastructure required by the user
- Simple and intuitive set-up in under 5 minutes
- Short-learning curve to proficiency
- Compatible with off the shelf guidewires and catheters

1. Research report from wet-lab with 9 experienced interventional radiologists. Set-up times and learning curve will vary with user.

Initial Target Market: Peripheral Vascular



INITIAL TARGET PROCEDURES (USA):
2.3M

ANNUAL SPENDING (USA):
$15B

TARGET PHYSICIANS (USA):
6,000

AVG. ANNUAL # OF PROCEDURES PER PHYSICIAN (USA):
~400

FACILITIES PERFORMING PROCEDURES (USA):
2,200 Hospitals
1,000 Ambulatory Centers

Source: AcuityMD database

Clinical Outcomes from ACCESS-PVI

Robotic manipulation of guidewires and catheters with LIBERTY® was successful in all cases, minimizing radiation exposure and maintaining a desirable safety profile[1]

Achieved
100%
Robotic Navigation Success in Every Case
(N = 20)

92%
Relative Reduction in Radiation Exposure

NO
Adverse Device Events Reported
(ADE = 0%)

Participating Physicians Reported LIBERTY Performed as Planned with
100%
Satisfaction

1. Cornelis F, Gandhi R, Rabkin D, Diaz-Cartelle J. Remote-controlled endovascular navigation with a miniature, single-use, robotic system. LBA15

First Mover Advantage

LIBERTY® was designed to eliminate barriers and enable adoption of robotics in endovascular procedures

Barriers to Adoption	Other Robotic Systems	LIBERTY® Endovascular Robotic System
Cost of acquisition	✓ **Large** capital investment ✓ **Disposable** procedure kit ✓ **Annual service agreement**	✓ **Single-use (disposable) device** with no **initial acquisition cost**
Procedure set-up time	✓ **20 minutes extra** compared to conventional surgery[1]	✓ **5 minutes** to set-up the robot[3]
Learning curve	✓ Average **40-100 cases** depending on the procedure[2]	✓ **Less than 5 cases**[3]
Device compatibility	✓ Some require use of **proprietary instruments and devices**	✓ Compatible with **off-the-shelf instruments and devices**
Complex integration	✓ Requires a **dedicated room** and **integration with hospital IT systems**	✓ Can be used in **any angio-suite** and **does not need to connect with hospital IT**

1. Analysis of Procedure Time in Robot-Assisted Surgery: Comparative Study in Laparoscopic Cholecystectomy, Computer Aided Surgery, 8:1, 24-29, DOI: 10.3109/10929080309146099.
2. Systematic review of learning curves in robot-assisted surgery; BJS Open 2020; 4: 27–44.
3. Research report from wet-lab with nine experienced interventional radiologists. Set-up times and learning curve will vary with user.

First Mover Advantage

LIBERTY® is the only commercially robotic system available in the US for peripheral endovascular procedures

Several companies are developing robotic solutions due to the attractive market and untapped potential

Microbot is uniquely positioned for success with our unique design and first mover advantage in the US market

Company	Status	Target Procedures	USA Commercial Availability	No Capital Equipment	No Maintenance Required	No Infrastructure Required	Competitive Outlook
microbot medical	On the Market (U.S.)	Peripheral Vascular	✓	✓	✓	✓	CE Mark expected in late in 2026; will explore additional markets that leverage FDA clearance.
Robocath	On the market (Europe, China)	Cardiology	X	X	X	X	Focused on Europe & China. Large capital system with high cost and complex integration.
LN ROBOTICS	On the market (Korea only)	Cardiology	X	X	X	X	Focused on Korea. Large capital system with high cost and complex integration.
Corindus Vascular Robotics	Development stage	Neurovascular	X	X	X	X	Exited US cardiology market. Changed strategy from PCI to focus on Neurovascular.
sentante (Latvia)	Development stage	Peripheral Vascular	X	X	X	X	Completed one case in humans. Clinical, regulatory and operational complexity are unknown.
nanoflex robotics	Development stage	Neuro Vascular	X	X	X	X	Pre-clinical. Focused on telerobotics with magnetic steering. Cost and operational complexity are unknown.

Attractive Reimbursement

Targeted procedures have an attractive outpatient reimbursement with capacity to incorporate new technologies including LIBERTY®

Procedure	Description	CPT Code(s)	Avg. Reimbursement
Y90 for Liver Cancer	Part 1 – Mapping procedure Part 2 – Embolization procedure	Dx Angiogram (75726) Coil placement (37242) Embolization (37243) Y90 particles (C2616)	**$43,990.21**
Peripheral Embolization	For BPH, Uterine Fibroids, Hemorrhoids, Knee Osteoarthritis	Dx Angiogram (75726) Bland particle embolization (37242)	**$15,734.00**
Lower Limb Revascularization	Below the knee Chronic total occlusions	Dx Angiogram (75726) Angioplasty (37242)	**$15,856.00**
Vascular Hemorrhage	Place intravascular coils or glue to stop bleeding	Dx Angiogram (75726) Coil placement (37244)	**$15,734.00**

2024 Medicare/Medicaid average reimbursement
Actual reimbursement will vary and may be adjusted for cost of living
Private insurance typically billed at a higher rate

Unique Business Model

The fully disposable feature of LIBERTY® offers an attractive business model to position LIBERTY® for commercial success by reducing barriers for entry and increase operational efficiencies for all stakeholders

No Capital Investment

- No special Capital Expense (CAPEX) approval required by the customer. LIBERTY® can be purchased from the Operational Expense (OPEX) budget which will expedite the purchasing process.
- Cost effective evaluation process for customers at their facility can expedite purchasing decision.
- Eliminates the Company's investment in an expensive upfront and ongoing capital equipment inventory build-up, shipping, storage and management.

No Maintenance Expense

- Eliminates the cost for Microbot to hire, train, and manage a dedicated field service department.
- Eliminates the cost for Microbot to build dedicated warehouses and maintain inventory of replacement parts.
- Eliminates the cost for customers to pay for service and maintenance expenses.
- Eliminates risk of equipment down time.

No Custom Infrastructure

- Eliminates the process of fitting the technology to each specific customer (and sometime within a health system), to reduce expenses and expedite purchasing decision.
- Eliminates the investment in establishing, training, supporting and supplying technical team to support installations.
- LIBERTY® does not require investment in dedicated customer staff to provide on-going robotic program support.

Continuous Consumable Revenue

- Recurring revenue stream based on per device usage (or more) for a single procedure.
- LIBERTY® is a single SKU (Stock Keeping Unit) that can be utilized across many procedures, physicians and departments.

Commercialization Timeline

Successful execution of regulatory, commercial and launch readiness strategies

Go-to-Market Strategy

Company positioned to accelerate market adoption of the LIBERTY® system

- Dedicated direct sales team in the U.S., supplement with distribution channels as needed
- Increase manufacturing and build inventory levels to meet anticipated demand
- Limited Market Release (LMR) in Q4 2025 followed by a Full Market Release (FMR) expected in early 2026

Building for Comprehensive Growth

Future growth will come from access to new markets (EMEA, Canada, etc.), spaces (cardiology, neurovascular) and usability (tele-intervention)

Active R&D Pipeline: Focused on next-generation robotic system that allows for increased usability in existing space (deep) and entering new spaces (wide).

Ongoing Development: Tele-intervention and autonomous robotics programs in progress.

Build a direct sales team in the U.S. from 4 to 12 territories by end of the year.

Expand to new markets: Establish commercial and operational infrastructure to support expansion into EMEA (Europe, Middle East, Asia).

Pursue CE Mark: Supplement FDA clearance to enter markets based on respective regulatory requirements.

Financial Strength

Capital-efficient operating model by eliminating upfront and ongoing expensive equipment inventory, logistics, and field service.

Frees capital to invest in high-return growth drivers, including Sales, Marketing, and Pipeline Development, enhancing shareholder value.

Strong balance sheet with ~$80M in cash by YE 2025 and a ~$2.5M/month burn rate in 2026, providing a favorable cash runway.

Global Intellectual Property Portfolio

LIBERTY® is protected by a strong and growing intellectual property portfolio.

Experienced Management Team

Harel Gadot
CEO, President & Chairman
LinkedIn

Simon Sharon
Chief Technology Officer
LinkedIn

Juan Diaz-Cartelle, MD
Chief Medical Officer
LinkedIn

Rachel Vaknin
Chief Financial Officer
LinkedIn

Earl Adamy
Vice President of Strategic Marketing & Business Dev
LinkedIn

Eran Cohen
Vice President of Global Integration
LinkedIn

Naama Moav
Vice President of HR
LinkedIn

Noa Ofer
Vice President of QA & RA
LinkedIn

Proven Commercial Leadership Team

Christina Bailey
Vice President of Sales USA
LinkedIn

Alon Tamir
Vice President of EMEA
LinkedIn

Allison Rosefort
Vice President of Marketing
LinkedIn

Justin Bourne
Director of Sales
LinkedIn

Elaina Romano
Sr. Director Internal Operations
LinkedIn

Dani Kulp
Director, Sales Training
LinkedIn

Michael Lytle
Manager, Sales Operations
& Analytics
LinkedIn

Lisa Dobbins
Sr. Director, Human Resources
LinkedIn

The Reason to Believe

Being the first and only robotic system for PI in the USA, and meeting its planned milestones in 2025, Microbot Medical is poised to build on this momentum in 2026.

- **FDA Clearance** obtained
- **Secured U.S. Based Logistics Partner** to Support Commercialization
- **Completed the Recruitment and onboarding** of the Commercial Leadership Team
- **Limited Market Release (LMR)** Commenced as plan
- **Initial Customers** Emory University Hospital, Tampa General Hospital, and other accounts
- **Strengthened Balance Sheet** ~80M available to Drive Commercialization Activities
- **Full Market Release** ~On Target for FMR

microbot medical

Contact Investor Relations

ir@microbotmedical.com
NASDAQ CM: MBOT